Purdue University, Eli Lilly and Co., and Merck & Co. have launched the Young Institute Pharmaceutical Manufacturing Consortium, a collaborative effort to pioneer advances in making medicines. Operating within Purdue’s William D. and Sherry L. Young Institute for Advanced Manufacturing of Pharmaceuticals, consortium partners will focus on advancing pharmaceutical manufacturing, according to a Jan. 17 news…
Lilly gets nod to market locally manufactured insulin in Egypt
Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership with Eva Pharma. The companies launched their collaboration in 2022 to deliver a sustainable supply of high-quality, affordable human and analog insulin. It wants to bring insulin to at least 1 million people annually living with diabetes in low- to…
Eli Lilly to invest $3B in Wisconsin manufacturing plant expansion
Eli Lilly (NYSE:LLY) announced that it plans to invest $3 billion in the expansion of its manufacturing facility in Kenosha County, Wisconsin. In April, Indianapolis-based Eli Lilly acquired the plant in Pleasant Prairie, Wisconsin, from sterile manufacturer Nexus. The company expects its investment to extend its global parenteral (injectable) product manufacturing network. It aims to…
Eli Lilly opens new $4.5B pharmaceutical manufacturing plant in Indiana
Eli Lilly (NYSE:LLY) announced today that it made a $4.5 billion investment to create the Lilly Medicine Foundry in Indiana. The new center offers capabilities for advanced manufacturing and drug development. Lilly expects to gain new ways to produce medicines while also scaling up manufacturing of medicines for clinical trials. Its first-of-its-kind facility combines research…
Lilly expands manufacturing footprint in Ireland
Eli Lilly and Co. recently announced that it’s spending $1 billion to expand its Limerick, Ireland, manufacturing site. The goal of the expansion, announced Sept. 12, is to increase the production of biologic active ingredients, including those for the company’s recently approved treatment for early symptomatic Alzheimer’s disease. The company announced in July that the…
Eli Lilly acquires new injectable medicine manufacturing plant
Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the…
Pharma manufacturing sees wave of investments in Europe
Over the past three months, the pharma sector has seen a string of investments in manufacturing facilities, especially in Europe. While the European economy lost momentum in 2023 owing to a high cost of living, weak external demand, and monetary tightening, the prospects for growth remain stronger with the EU GDP growth forecast to improve…
Lilly acquires Point Biopharma amid third FDA rejection in 2023
Eli Lilly and Company has recently received its third FDA rejection for the year 2023. The most recent came for lebrikizumab, the company’s investigational treatment for atopic dermatitis. FDA made the decision following an inspection of a third-party contract manufacturing organization. The agency had no complaints concerning the clinical data, safety, or labeling of lebrikizumab,…
Lilly wraps up acquisition of Versanis, marking the fifth largest pharma deal of 2023
Eli Lilly just wrapped up its acquisition of Versanis Bio in a $1.9 billion deal, the pharma giant announced today. The deal marks Lilly’s latest move to build up its pipeline of potential obesity and diabetes treatments, which promises to be a notable growth area for the company. Lilly recently completed its submission of tirzepatide…
The battle of the bulge: Semaglutide and tirzapatide could be new weight-loss warriors
A pair of weight-loss drugs — semaglutide and tirzapatide — could reshape the way we view and treat obesity, according to a Moody’s report dated May 18. The ratings firm notes that Novo Nordisk could benefit from a first-mover advantage in the obesity market as it now has two novel weight loss drugs on the…